NYSE: HCA · Health Care Facilities
HCA Healthcare
HCA Healthcare, based in Nashville, is one of the leading health care services companies in the United States. At the end of 2025 it operated 190 hospitals (179 general acute care, seven behavioral and four rehabilitation) plus 121 freestanding ambulatory surgery centers, 31 endoscopy centers and other outpatient facilities, with about 320,000 employees. It manages its hospitals in three operating groups (National, Atlantic and American). 2025 revenues rose 7% to $75,600 million and net income attributable to HCA to $6,784 million, or $28.33 per share. Managed care and other insurers paid about half of revenue, with Medicare and Managed Medicare another third. HCA returns cash through buybacks ($10 billion authorizations in 2025 and 2026) and a dividend raised to $0.78 per quarter in 2026.
Last updated
Analysis last edited: October 31, 2026 · Financial data fetched: October 25, 2026 03:39 (SEC EDGAR) · Source 10-K filed: February 10, 2026
Built on10-K FY2025 · filed 2026-02-1010-Q (quarter ended 2026-09-30) · filed 2026-10-29Proxy statement (2026)
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
01
At a glanceFrom SEC data
Eight headline measures, each placed among the companies covered on this site.
- Revenue growthCAGRSmooths out year-to-year swings into "grew X% a year on average." Makes growth pace comparable across companies of very different sizes.
- 8.0%
- Operating marginOperating marginHow many cents of operating profit are left per dollar of revenue. Reflects pricing power and cost structure.
- —
- ROIC minus WACCROIC − WACC spreadThe difference between ROIC and WACC. Consistently positive implies value creation; consistently negative implies value destruction.
- —
- Net debt ÷ EBITDAEBITDAOperating income with D&A added back. A rough proxy for cash-generating power that’s less distorted by capital intensity, depreciation method, or financing/tax differences than net income.
- —
- Cash conversionOperating CF ÷ net income (cash conversion)How much of reported profit shows up as actual cash. 1x or higher means profit is backed by cash.
- 1.86x
- Dividend raisesDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year).
- 5 of 5
- P/E todayP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing.
- 16.5x
- Betaβ (beta)How much a stock moves, on average, for a 1% move in the overall market. Above 1 means more volatile than the market, which raises the return shareholders require. This site computes it from about 2.5 years (roughly 130 weeks) of weekly returns, built from Yahoo Finance daily prices, regressed against an S&P 500 ETF (SPY) as the market proxy, then applies the well-known long-run mean-reversion adjustment (0.67 × β + 0.33) as the WACC default.
- 0.53
Higher than 47% of 372 non-financial companies
Average yearly growth over the years shown
Latest fiscal year (FY2025)
Return on capital above (or below) its estimated cost
Below 0 means more cash than debt
Higher than 66% of 349 non-financial companies
Operating cash flow ÷ net income
Years the dividend per share rose, of the last 5
Latest close 2026-11-04; trailing 12 months to 2026-09-30
Above 1 = moves more than the market
Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.
02
Valuation todayFrom SEC data
Price-based measures at the latest close, next to the same measures at the last fiscal year-end.
Share price$496.81close on 2026-11-04
Market cap$111.59B
- P/EP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing. today
- 16.5x
- P/BP/BShare price ÷ book value per share. Below 1x means the market values the company below its accounting net worth. This site uses the closing price nearest the fiscal year-end and highlights sub-1x readings. today
- —
- EV/EBITDAEV/EBITDAEnterprise value (≈ market cap + interest-bearing debt − cash) as a multiple of EBITDA — roughly, "how many years of EBITDA to buy the whole company." Lower is generally viewed as cheaper, and it’s more comparable than P/E across companies with different debt loads or depreciation policies. This site excludes noncontrolling interests from the EV calculation. today
- —
- FCF yieldFree cash flow (FCF)Operating CF minus capital expenditures — cash generated by the business after funding its own investment, available for dividends, buybacks, acquisitions, or debt paydown. Acquisitions and securities purchases (also in investing CF) are not subtracted, so FCF can be positive in a year when total investing CF exceeds operating CF. today
- 6.9%
- Dividend yieldDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year). today
- 0.6%
At FY2025 year-end: 16.5x
Earnings: trailing 12 months to 2026-09-30
At FY2025 year-end: —
Book value at FY2025 year-end
At FY2025 year-end: —
EBITDA for FY2025
At FY2025 year-end: 7.3%
Free cash flow for FY2025
Dividends per share for FY2025
“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.
03
What changed since last earningsFrom SEC data
The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.
Quarter ended Sep 30, 2026.
- Revenue$19.16B → $19.85B (vs. a year earlier)↑ +3.6%$19.16B → $19.85B (vs. a year earlier)
- Net income$1.64B → $1.58B (vs. a year earlier)↓ −3.9%$1.64B → $1.58B (vs. a year earlier)
- Diluted EPS$6.96 → $7.27 (vs. a year earlier)↑ +4.5%$6.96 → $7.27 (vs. a year earlier)
- Cash$1.01B → $908M (vs. previous quarter-end)↓ −10.4%$1.01B → $908M (vs. previous quarter-end)
- Long-term debt$45.83B → $44.77B (vs. previous quarter-end)↓ −2.3%$45.83B → $44.77B (vs. previous quarter-end)
Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.
From the earnings release of Oct 27, 2026.
Management outlook • Issued
Now expects full-year results in the upper half of its 2026 guidance ranges. Source sentence
The Company now believes its full year operating results will be in the upper half of its 2026 estimated guidance ranges previously issued on July 14, 2026.
Key changes
Net income down 3.9% to $1.579B. Source sentence
Net income attributable to HCA Healthcare, Inc. declined 3.9 percent to $1.579 billion
Diluted EPS up 4.5% to $7.27. Source sentence
Diluted earnings per share increased 4.5 percent to $7.27 per diluted share, and diluted earnings per share, as adjusted, increased 3.7 percent to $7.22 per diluted share
Same facility admissions up 2.7%. Source sentence
Same facility admissions increased 2.7 percent and same facility equivalent admissions increased 3.0 percent
Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗
04
Company profileFrom SEC dataShow
- Legal name
- HCA Healthcare, Inc.
- Headquarters
- NASHVILLE, TN
- Fiscal year end
- 12/31
- Exchange & ticker
- NYSE: HCA
- Industry
- Health Care Facilities
- CIK
- 860730
- Website
- https://hcahealthcare.com/ ↗
Workforce (as of FY2025 year-end)
Employees
320,000
Source: Form 10-K (FY2025) cover page and business description
05
Earnings calendarFrom SEC dataShow
When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.
Next report
Q4 FY2026
Quarter end: December 2026. In past years, Q4 results were released 24–30 days after quarter end (Jan 27, 2026; Jan 24, 2025; Jan 30, 2024). No date has been announced in the sources this site uses.
Reporting pattern
- Fiscal year ends around December 31.
- Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
- Earnings releases came 23–30 days after quarter end over the last 12 quarters.
| Quarter | Quarter ended | Earnings release (8-K) | Report filed (10-Q / 10-K) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | Oct 27, 2026 (+27 days) | Oct 29, 2026 10-Q (+29 days) |
| Q2 FY2026 | Jun 30, 2026 | Jul 24, 2026 (+24 days) | Jul 28, 2026 10-Q (+28 days) |
| Q1 FY2026 | Mar 31, 2026 | Apr 24, 2026 (+24 days) | Apr 29, 2026 10-Q (+29 days) |
| Q4 FY2025 | Dec 31, 2025 | Jan 27, 2026 (+27 days) | Feb 10, 2026 10-K (+41 days) |
| Q3 FY2025 | Sep 30, 2025 | Oct 24, 2025 (+24 days) | Oct 30, 2025 10-Q (+30 days) |
| Q2 FY2025 | Jun 30, 2025 | Jul 25, 2025 (+25 days) | Aug 4, 2025 10-Q (+35 days) |
| Q1 FY2025 | Mar 31, 2025 | Apr 25, 2025 (+25 days) | May 1, 2025 10-Q (+31 days) |
| Q4 FY2024 | Dec 31, 2024 | Jan 24, 2025 (+24 days) | Feb 14, 2025 10-K (+45 days) |
| Q3 FY2024 | Sep 30, 2024 | Oct 25, 2024 (+25 days) | Oct 31, 2024 10-Q (+31 days) |
| Q2 FY2024 | Jun 30, 2024 | Jul 23, 2024 (+23 days) | Jul 29, 2024 10-Q (+29 days) |
| Q1 FY2024 | Mar 31, 2024 | Apr 26, 2024 (+26 days) | May 2, 2024 10-Q (+32 days) |
| Q4 FY2023 | Dec 31, 2023 | Jan 30, 2024 (+30 days) | Feb 16, 2024 10-K (+47 days) |
Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.
06
Flagship products & servicesSite analysis
Hospitals
General acute care hospitals
179 general acute care hospitals offering medical, surgical, emergency and other services.
Hospitals
Behavioral and rehabilitation hospitals
Seven behavioral and four rehabilitation hospitals.
Outpatient
Ambulatory surgery and endoscopy centers
121 freestanding ASCs and 31 freestanding endoscopy centers.
From the Form 10-K, FY2025.
U.S., worldwide and country/regional share of flagship products/services
Only shares the company itself states (in its filings or press releases, sometimes citing a research firm) are shown. Scope and timing vary by figure — treat these as approximate.
Hospital services
U.S. health care services
U.S. share
One of the leading
Company-disclosed“HCA Healthcare, Inc. is one of the leading health care services companies in the United States.”
Worldwide share
—
Not disclosed
07
Recent strategic focusSite analysis
Recent developments.
2025 results
Revenues $75,600M (+7.1%); net income attributable to HCA $6,784M; EPS $28.33.
Source: Form 10-K (FY2025)
Q3 2026
Revenues $19.849B (+3.6%); net income attributable $1.579B (−3.9%); diluted EPS $7.27 (+4.5%); same-facility admissions +2.7%. HCA repurchased 7.23M shares for $2.97B in the quarter and expects full-year results in the upper half of its guidance ranges.
Source: Q3 2026 earnings release
Capital return
$10B buyback authorized in January 2026; quarterly dividend raised to $0.78.
Source: Form 10-K (FY2025)
Capex ÷ D&A (FY2025)
1.40x
Well above depreciation — expansion-stage investment
formulacapital expenditures ÷ depreciation & amortization
e.g.$4,944M ÷ $3,523M = 1.40x
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
M&A spend (6-year total)
$1.3B
Latest year: $397M
Cash-flow-statement spending on acquisitions, net of cash acquired
Where the money goes, over time
Unit: $M. Capex went from $2.84B in FY2020 to $4.94B in FY2025
- Capex
- M&A spend
formulacapital expenditures ÷ depreciation & amortization
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10
08
Key figures at a glanceFrom SEC data
FY2020–FY2025, 6 years.
Revenue (FY2025)
$75.6B
As reported in the 10-K
Revenue CAGR (5 years)
+8.0%▲favorable
formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1
e.g.($75,600M ÷ $51,533M) ^ (1÷5) − 1 = 8.0%
termsCAGR · ^ (exponent) · Revenue (net sales)
Operating margin (FY2025)
—
formulaoperating income ÷ revenue × 100
ROE (FY2025)
—▼caution
6-year average: 656.3%
As reported in the 10-K
P/B (FY2025 end)
—
Period-end (fiscal year-end) value, not today's P/B
EV/EBITDA (FY2025 end)
—
formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)
termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)
Period-end (fiscal year-end) value, not today's multiple
- ▲
Revenue grew +8.0% a year over 5 years (strong growth)
From $51.53B in FY2020 to $75.6B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.
- ▼
Equity ratio is -9.9% (relatively heavy reliance on debt)
The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).
- ▲
Free cash flow was positive in 6 of 6 years
Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.
- ▲
ROE averaged 656.3% over 6 years (latest: —)
How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.
09
Business modelSite analysis
Business Model Canvas
The whole company in nine blocks. Left side: how it delivers (partners, activities, resources, costs). Right side: who it serves and how it earns. Every entry comes from the company’s filings shown on this page.
08 · who helps
Key partners
No partners or suppliers named in the filings.
07 · what it does
Key activities
- Inpatient and emergency care
- Outpatient surgery, endoscopy and imaging
- Behavioral and rehabilitation care
06 · what it draws on
Key resources
- About 320,000 employees (incl. about 90,000 part-time and PRN)
- 190 hospitals and outpatient centers
- Affiliated physicians and nurses
02 · why customers buy
Value propositions
- Acute care hospitals and outpatient facilities in its local markets.
04 · how it keeps them
Customer relationships
- Contracts with commercial insurers and government programs that pay for care; relationships with physicians.
03 · how it reaches them
Channels
- Its own hospitals, surgery centers, freestanding ERs and urgent care centers.
01 · who it serves
Customer segments
- Patients covered by managed care and other insurers (48.9% of 2025 revenue)
- Medicare and Managed Medicare (32.7%)
- Medicaid and Managed Medicaid (12.7%)
09 · where money goes
Cost structure
FY2025, share of revenue ($75.6B)
- Selling, general & administrative0.7%
Depreciation & amortization (inside the costs above): $3.52B. Capital spending: $4.94B.
Source: Form 10-K income statement and cash-flow statement (SEC XBRL).
05 · how money comes in
Revenue streams
- Revenues $75,600M (2025)
- Atlantic Group $24,709M, American Group $26,445M, National Group $21,278M
Value propositions, channels and customer relationships: Form 10-K (FY2025)
Operates acute care hospitals and outpatient facilities and is paid by commercial insurers, Medicare, Medicaid and patients for inpatient and outpatient services.
01 what it draws on
Inputs & resources
- About 320,000 employees (incl. about 90,000 part-time and PRN)
- 190 hospitals and outpatient centers
- Affiliated physicians and nurses
02 what it does
Activities
- Inpatient and emergency care
- Outpatient surgery, endoscopy and imaging
- Behavioral and rehabilitation care
03 who it serves
Customers
- Patients covered by managed care and other insurers (48.9% of 2025 revenue)
- Medicare and Managed Medicare (32.7%)
- Medicaid and Managed Medicaid (12.7%)
04 how money comes in
How it earns
- Revenues $75,600M (2025)
- Atlantic Group $24,709M, American Group $26,445M, National Group $21,278M
How the business makes money
- International managed care and other insurers revenue was $1,864M in 2025.
- Shareholders’ equity attributable to HCA is negative after large buybacks.
- Board authorized $10B buyback programs in January 2025 and January 2026.
Government & regulation around the business
Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.
HCA’s volumes depend on Exchange subsidies and Medicare/Medicaid, and antitrust and expansion rules apply.
Government funding & tax credits
Exchange subsidy expiry
Expects effects from the expiration of enhanced premium tax credits at end-2025.
Constrains the businessTouches: CustomersSource: Form 10-K (FY2025)
Approvals & licenses
Expansion rules
Federal and state rules can limit its ability to expand.
Constrains the businessTouches: ActivitiesSource: Form 10-K (FY2025)
Trade & export rules
Tariffs and trade rules
Tariffs may affect its supply chain.
Constrains the businessTouches: Inputs & resourcesSource: Form 10-K (FY2025)
Revenue by segment (FY2025)
Unit: $M — bar length = revenue, (%) = share of total company revenue
American Group
26,445 (37%)Atlantic Group
24,709 (34%)National Group
21,278 (29%)
Source: Form 10-K (FY2025) — Segment information Operating-group revenues; other operations make up the rest of the $75,600M total.
10
Contract structureSite analysisShow
Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.
11
Customers & suppliersSite analysis
Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.
Customers
Patients and their payers: commercial insurers, Medicare, Medicaid and self-pay.
Named by the company
No single customer is named.
Suppliers
Medical supply and pharmaceutical suppliers and group purchasing.
Named by the company
No supplier is named as material.
12
Competitors & peersSite analysis
Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.
HCA’s hospitals compete with other hospitals, including not-for-profit and government-owned facilities, specialty hospitals and outpatient providers; the 10-K names no specific competitors.
Competitors named in the 10-K
The 10-K names competitor categories only.
Peer group the company chose
Compensation peer group (24 companies), from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.
Health care services, insurance, pharmaceutical, medical supply and related companies with median 2024 revenue of $60.0B.
- Abbott Laboratoriessite ↗
- AbbViesite ↗
- Amgensite ↗
- Bristol-Myers Squibbsite ↗
- Cardinal Healthsite ↗
- Cencorasite ↗
- Centenesite ↗
- CVS Healthsite ↗
- Danahersite ↗
- Elevance Healthsite ↗
- Eli Lillysite ↗
- Gilead Sciencessite ↗
- Humanasite ↗
- Johnson & Johnsonsite ↗
- McKessonsite ↗
- Medtronicsite ↗
- Merck & Co.site ↗
- Molina Healthcaresite ↗
- Pfizersite ↗
- Strykersite ↗
- Tenet Healthcaresite ↗
- The Cigna Groupsite ↗
- Thermo Fisher Scientificsite ↗
- UnitedHealth Groupsite ↗
Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.
13
Six years of financialsFrom SEC data
Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.
Revenue over time
Unit: $M
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10
Profit over time (operating → net)
Unit: $M
- Pretax income
- Net income
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10
Margins over time
Unit: %
- Operating margin
- Net margin
formulaoperating income ÷ revenue × 100
formulanet income attributable to the company ÷ revenue × 100
Cash flow over time
Unit: $M (below zero = cash went out)
- Operating CF
- Investing CF
- Free CF
formulacash flow from operations − capital expenditures
termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10
Financial stability & capital efficiency
Unit: %
- Equity ratio
- ROE
formulatotal equity ÷ total assets × 100 (as reported in the 10-K)
termsStockholders’ equity · Total assets
formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)
termsNet income (attributable to the company) · Stockholders’ equity
Earnings per share (EPS) and dividend per share
Unit: $
- EPS
- Dividend per share
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10
| Line item | FY202010-K on EDGAR ↗ | FY202110-K on EDGAR ↗ | FY202210-K on EDGAR ↗ | FY202310-K on EDGAR ↗ | FY202410-K on EDGAR ↗ | FY202510-K on EDGAR ↗ |
|---|---|---|---|---|---|---|
| Income statement ($M) | ||||||
| Revenue | 51,533 | 58,752 | 60,233 | 64,968 | 70,603 | 75,600 |
| Pretax income | 5,430 | 9,833 | 8,580 | 7,706 | 8,523 | 9,832 |
| Net income (attributable) | 3,754 | 6,956 | 5,643 | 5,242 | 5,760 | 6,784 |
| Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100 | — | 14.0% | 2.5% | 7.9% | 8.7% | 7.1% |
| Net margincalcnet income attributable to the company ÷ revenue × 100 | 7.3% | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% |
| Balance sheet ($M) | ||||||
| Total assets | 47,490 | 50,742 | 52,438 | 56,211 | 59,513 | 60,720 |
| Total equity | 2,892 | 1,489 | -73 | 1,060 | 555 | -2,771 |
| Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable | 31,004 | 34,579 | 38,084 | 39,593 | 43,031 | 44,285 |
| Equity ratio | 1.2% | -1.8% | -5.3% | -3.2% | -4.2% | -9.9% |
| ROE | 656.3% | — | — | — | — | — |
| Cash flow ($M) | ||||||
| Operating CF | 9,232 | 8,959 | 8,522 | 9,431 | 10,514 | 12,636 |
| Investing CF | -3,393 | -2,643 | -3,389 | -5,317 | -4,933 | -4,988 |
| Financing CF | -4,677 | -6,655 | -5,656 | -4,094 | -4,582 | -8,550 |
| Free cash flowcalccash flow from operations − capital expenditures | 6,397 | 5,382 | 4,127 | 4,687 | 5,639 | 7,692 |
| Cash and equivalents | 1,793 | 1,451 | 908 | 935 | 1,933 | 1,040 |
| Per share & other | ||||||
| EPS ($) | 10.93 | 21.16 | 19.15 | 18.97 | 22.00 | 28.33 |
| BVPS ($) | 1.69 | -3.05 | -9.98 | -6.68 | -10.00 | -26.83 |
| Dividend per share ($) | 0.43 | 1.92 | 2.24 | 2.40 | 2.64 | 2.88 |
| Payout ratiocalcdividend per share ÷ diluted EPS × 100 | 3.9% | 9.1% | 11.7% | 12.7% | 12.0% | 10.2% |
| P/E (x) | 15.1 | 12.1 | 12.5 | 14.3 | 13.6 | 16.5 |
| P/B (x)calcfiscal year-end closing price ÷ book value per share | 97.59 | — | — | — | — | — |
P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.
Last 8 quarters
Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.
| Quarter ended | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-09-30 | $19.85B+3.6% | $1.58B-3.9% | $7.27 |
| 2026-06-30 | $20.23B+8.7% | $1.7B+2.8% | $7.62 |
| 2026-03-31 | $19.11B+4.3% | $1.62B+0.6% | $7.15 |
| 2025-12-31 † | $19.51B+6.7% | $1.88B+30.6% | — |
| 2025-09-30 | $19.16B | $1.64B | $6.96 |
| 2025-06-30 | $18.61B | $1.65B | $6.83 |
| 2025-03-31 | $18.32B | $1.61B | $6.45 |
| 2024-12-31 † | $18.29B | $1.44B | — |
† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.
14
Is ROIC above WACC?From SEC data
ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.
Not enough data (operating income, equity, etc.) to compute ROIC/WACC.
15
What the price implies (DCF)From SEC data
A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.
Growth the price implies (price on 2026-11-04)
1.8%
Perpetual FCF growth: g = r − FCF ÷ EV = 6.7% − 5.0%
Past FCF growth (FY2020–FY2025)
+3.8%
Compound annual rate, 5 years
Past revenue growth (FY2020–FY2025)
+8.0%
Compound annual rate, 5 years
Inputs (FY2025): free cash flow $7.69B (operating CF − capex); enterprise value $154.83B = market cap $111.59B (latest close, 2026-11-04) + debt $44.29B − cash and short-term investments $1.04B; r = WACC of 6.7% using this page’s default assumptions (β 0.53, risk-free 5.0%, market premium 5.5%).
Three WACC scenarios
The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.
Try your own assumptions
V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.
Theoretical enterprise value
$156.98B
FCF $7.69B ÷ (6.7% − 1.8%)
Theoretical ÷ actual enterprise value
1.01x
Above 1x: these assumptions value the business above the market did
How sensitive the answer is
Theoretical ÷ actual enterprise value for each combination of r and g.
| g \ r | 4.7% | 5.7% | 6.7% | 7.7% | 8.7% |
|---|---|---|---|---|---|
| 0% | 1.06x | 0.87x | 0.74x | 0.65x | 0.57x |
| 2% | 1.84x | 1.34x | 1.06x | 0.87x | 0.74x |
| 4% | 7.10x | 2.92x | 1.84x | 1.34x | 1.06x |
| 6% | — | — | 7.10x | 2.92x | 1.84x |
| 8% | — | — | — | — | 7.10x |
A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.
16
Earnings qualityFrom SEC dataShow
The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.
- ✓
Operating CF ÷ net income: averages 1.79x
Profit is backed by cash coming in.
- ✓
Accrual ratio (latest): -9.7%
A small share of profit rests on accounting estimates.
- ✓
Days sales outstanding: 50 → 52 days
No major slowdown in collecting on sales.
Operating CF vs. net income
Unit: $M — operating CF above net income means profit is backed by cash
- Operating CF
- Net income
formulacash flow from operations ÷ net income attributable to the company
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formula(net income − operating CF) ÷ average total assets × 100
termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10
Receivables & inventory days
Unit: days — days grow when receivables or inventory build up faster than sales
- Days sales outstanding
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
termsInventory · Cost of revenue (COGS)
Worked examples (latest period)
formulacash flow from operations ÷ net income attributable to the company
e.g.$12,636M ÷ $6,784M = 1.86x
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formulaoperating income ÷ income before income taxes × 100
termsOperating income · Income before income taxes (pretax income)
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
e.g.($10,751M + $10,867M) ÷ 2 ÷ $75,600M × 365 = 52 days
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
termsInventory · Cost of revenue (COGS)
17
Who holds the sharesFrom SEC dataShow
How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.
Institutions, insiders and everyone else, 13F holdings as of 2026-06-30
“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.
- Held by 13F filers
- 62.1%
- Directors & officers (shares)
- 1.5%
- Everyone else (est.)
- 36.4%
- Directors & officers (voting power)
- 1.5%
- Institutional-ownership rank
- 403 of 416
- Beta (adjusted)
- 0.53
individuals and other non-13F holders
no separate voting figure; shown as shares
1 = most institutional; 97% of covered companies have more
above 1 = swings more than the market
- 134.5M shares reported by 1,338 13F filers ÷ 216.5M shares outstanding on 2026-07-24. Option positions are excluded.
- Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days.
- A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.
Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-03-13 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-07-24)
18
Strengths & weaknessesSite analysis
Strengths
1. Scale
190 hospitals and a large outpatient network across its markets.
Evidence: Form 10-K (FY2025)
2. Growing cash flow
Operating cash flow rose from $9,431M (2023) to $12,636M (2025).
Evidence: Form 10-K (FY2025)
3. Shareholder returns
Dividend per share rose from $1.92 (2021) to $2.88 (2025) and $0.78 per quarter in 2026; share count fell from 339M (2020) to 225M (2025).
Evidence: Form 10-K (FY2025)
Weaknesses
1. Leverage
Interest-bearing debt of about $44.3B at end-2025 and negative equity attributable to HCA.
Evidence: Form 10-K (FY2025)
2. Rising costs
Other operating expenses rose to $5,043M in Q2 2026 from $3,793M, mainly Medicaid supplemental program expenses and professional fees, and to $4,548M (23.0% of revenue) in Q3 2026 from $4,161M.
Evidence: Form 10-Q (quarter ended 2026-06-30); Q3 2026 earnings release
19
What draws investors to itSite analysis
Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.
P/E (FY2025)
16.5x
Price at fiscal year-end ÷ diluted EPS
Dividend yield (FY2025)
0.62%
Dividends per share ÷ fiscal year-end price
Payout ratio (FY2025)
10%
Dividends per share ÷ diluted EPS
FCF yield (FY2025)
7.3%
(Operating CF − capex) ÷ market cap
1. Buybacks
Share count fell about one-third from 2020 to 2025.
- What has to hold
- Cash flow stays strong.
- The other side
- Higher debt and negative equity.
Evidence: Form 10-K (FY2025)
2. Dividend growth
Quarterly dividend raised to $0.78 in 2026 from $0.72.
- What has to hold
- Earnings keep growing.
- The other side
- Reimbursement risk.
Evidence: Form 10-K (FY2025)
Book value per share is negative because equity attributable to HCA is negative after buybacks. HCA does not report operating income. M&A for 2023–2025 is acquisitions of hospitals and health care entities.
20
ResilienceSite analysisShow
How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.
1. Financial buffer (FY2025)
Cash & short-term investments ÷ debt due within a year
0.2x
$1.04B vs. $4.89B
Interest coverage (operating income ÷ interest expense)
Not disclosed
The income statement has no operating income line.
Free cash flow ÷ dividends paid
11.3x
$7.69B vs. $679M (FCF = operating CF − capex)
2. Worst year in the record, and the recovery
| Figure | Worst year-over-year change | Back to the prior level? |
|---|---|---|
| Revenue | No decline in the record | — |
Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.
3. Business resilience (from the 10-K)
Profitable through 2020
Net income attributable to HCA was $3,754M in 2020.
Source: Form 10-K (FY2025)
21
Legal & regulatory mattersSite analysisShow
Lawsuits, government investigations, enforcement actions and settlements the company discloses — where each stands, what is at stake, and what comes next. From the 10-K's Legal Proceedings and contingencies note, the latest 10-Q, and 8-Ks.
HCA operates in a litigious, highly regulated industry and faces ordinary-course malpractice, qui tam and government inquiries; it separately discloses a California district attorney investigation of waste disposal.
1 open matter
California waste disposal investigation
PendingEnvironmentalDistrict Attorneys of four California counties v. HCA affiliate
In December 2023 District Attorneys in four California counties began investigating waste disposal practices at HCA’s California facilities; HCA does not expect a material impact.
Company statement: Other proceedings are described as ordinary-course and not expected to be material.
Based on Form 10-K (FY2025) — Item 3, Legal Proceedings, reviewed 2026-10-25. Routine ordinary-course claims are not listed. “Major” is this site’s judgment of which matters could materially affect results.
22
Risks (including geopolitical)Site analysis
Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.
Risk map
Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).
Likelihood →
"Company disclosure" vs. "this site’s assessment"
The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.
Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.
- 1Law & regulation
Reimbursement changes
- Company disclosure (summarized from the 10-K)
- Medicare and Medicaid payment changes, state budget pressure and federal actions could reduce revenue.
- Company’s stated mitigation
- Not stated in the filings.
- This site’s assessment
- Impact High / Likelihood High
- 2Labor & workforce
Staffing
- Company disclosure (summarized from the 10-K)
- Competes for nurses and other professionals; salaries and benefits were 43.5% of 2025 revenue.
- Company’s stated mitigation
- Not stated in the filings.
- This site’s assessment
- Impact Med / Likelihood High
- 3Competition & technology shift
Local competition
- Company disclosure (summarized from the 10-K)
- Competes with not-for-profit and government hospitals, specialty hospitals and ASCs.
- Company’s stated mitigation
- Not stated in the filings.
- This site’s assessment
- Impact Med / Likelihood High
- 4Law & regulation
Investigations and litigation
- Company disclosure (summarized from the 10-K)
- Subject to government investigations, qui tam suits and malpractice claims.
- Company’s stated mitigation
- We continue to monitor all aspects of our business and have developed a comprehensive ethics and compliance program that is designed to meet or exceed applicable federal guidelines and industry standards.
- This site’s assessment
- Impact Med / Likelihood Med
- 5Disaster
Natural disasters
- Company disclosure (summarized from the 10-K)
- Hurricanes such as Milton and Helene can disrupt facilities.
- Company’s stated mitigation
- We maintain property insurance coverage for claims in excess of deductibles and self-insured retention levels generally at $110 million per occurrence ($120 million effective January 1, 2026) to address the impact of physical damage to our facilities and for business interruption losses.
- This site’s assessment
- Impact Med / Likelihood Med
23
What changed in the risk factorsFrom SEC data
Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.
New or substantially reworded (8)
As of December 31, 2025, our total indebtedness was $46.492 billion. Read more
As of December 31, 2025, we had availability of $5.779 billion under our senior unsecured credit facility (after giving effect to all issued and outstanding letters of credit and our intention to maintain a minimum available borrowing capacity equal to the aggregate amount outstanding under the commercial paper program ($2.207 billion as of December 31, 2025)). Our indebtedness could have important consequences, including:
Our operations could be impaired by a failure in or breach of our information systems or those of third parties on whose systems our business relies.
Failure to effectively manage change associated with our technology, resiliency and other initiatives, including with respect to the implementation of a new EHR platform, may adversely affect our business, services and results of operations.
We utilize multiple integrated software and hardware operating systems across our operations, including in our hospitals. Read more
Although we continually monitor these systems and strive to design our policies, programs and processes to preserve or manage these systems, such processes may not be effective and are subject to weaknesses and failures, including human error, data limitations, process delays, system outages, cybersecurity incidents or failed controls. Failure to effectively preserve or manage data accurately, timely and completely may adversely affect its quality and reliability and impair our ability to manage business needs, the provision of care, strategic decision-making and operations. We employ change management methodologies to plan, test and execute system upgrades and improvements. However, we cannot guarantee that our systems will operate as designed or that the…
We are implementing a new EHR platform across our facilities, which is complex and time-intensive. Read more
Significant internal and external resources have been, and will continue to be, required for successful implementation, including resources to train colleagues. Complexity or delay in implementation may require substantial additional time and expense and divert management’s attention from other strategic priorities, which, in turn, could adversely affect our business, results of operations or financial condition. While we have taken steps intended to mitigate implementation risks, including staged deployments in certain facilities, there is no guarantee these mitigation efforts will be effective.
Further, we are executing financial resiliency initiatives designed to generate efficiencies and cost reductions that we expect will offset in part the adverse effects on our business from recent health care policy reforms, including the expiration of the enhanced premium tax credits and changes resulting from the FBA. Our ability to realize the benefits from these financial resiliency initiatives is subject to known and unknown risks and uncertainties, and failure to realize the expected benefits may have an adverse effect on our business and results of operations.
Legislation and administrative actions at the federal and state levels may also impact the funding for, or structure or administration of, the Medicaid program, including through changes to Medicaid supplemental payments and SDP arrangements. For example, the FBA includes significant health care policy reforms that are expected to result in Medicaid spending reductions and changes in administration of state Medicaid programs. Among other changes, the law makes significant changes to Medicaid financing mechanisms, including restrictions intended to reduce the federal matching funds received by state Medicaid programs, such as limitations on provider tax arrangements and SDP arrangements. The FBA requires HHS to revise regulations governing SDP arrangements to cap total payment rates paid by Medicaid managed care organizations for specified services, tying caps to Medicare payment rates…
flexibilities in the administration of state Medicaid programs. Read more
For example, structural and other changes to Medicaid supplemental payment programs and SDP arrangements, both of which are subject to CMS approval, could result in our revenues from such payments being reduced or eliminated. Among other measures, states may divert funding for SDP arrangements from other payment programs or direct payments to a specific subset of providers, and we may not satisfy applicable criteria.
No longer in the text (4)
As of December 31, 2024, our total indebtedness was $43.031 billion. Read more
As of December 31, 2024, we had availability of $3.486 billion under our senior secured cash flow credit facility and $4.500 billion under our senior secured asset-based revolving credit facility, after giving effect to letters of credit and borrowing base limitations. Our indebtedness could have important consequences, including:
Under our asset-based revolving credit facility, borrowing availability is subject to a borrowing base of 85% of eligible accounts receivable less customary reserves, with any reduction in the borrowing base that results in the borrowing base falling below the amount committed by the lenders thereunder commensurately reducing our ability to access this facility as a source of liquidity. In addition, under the asset-based revolving credit facility, when (and for as long as) the combined availability under our asset-based revolving credit facility and the revolving facility under our senior secured cash flow credit facility is less than a specified amount for a certain period of time or, if a payment or bankruptcy event of default has occurred and is continuing, funds deposited into any of our depository accounts will be transferred on a daily basis into a blocked account with the…
We may not be adequately reimbursed by third-party payers for services involving new technology.
As health care technology continues to advance, the price of purchasing new technology has significantly increased for providers. Read more
Some payers have not adapted their payment systems to adequately cover the cost of new technology used to treat patients. If reimbursement from third-party payers for services involving new technology does not sufficiently cover our purchasing costs, we may be unable to acquire new technology. Even without sufficient third-party reimbursement, we may acquire or utilize new technology in order to treat our patients. In either case, our results of operations and financial position could be adversely affected.
7 more paragraphs differ; the filings below have the full text.
Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 10, 2026 ↗ with the 10-K filed Feb 14, 2025 ↗.
24
What to watch going forwardSite analysis
- Medicaid supplemental payment programs and federal reimbursement changes.
- Labor cost trends.
- Pace of share buybacks against debt levels.
- California waste disposal investigation.
25
Source documentsShow
This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.
Other sources referenced in the analysis
Last updated
Analysis last edited: October 31, 2026 · Financial data fetched: October 25, 2026 03:39 (SEC EDGAR) · Source 10-K filed: February 10, 2026
Built on10-K FY2025 · filed 2026-02-10Proxy statement (2026)
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
This page is this site’s own analysis based on public information, and does not represent HCA Healthcare’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.